N※N

Lonza May Sell Capsule Business for Up to $1 Billion

  //business-finance.news-articles.net/content/202 .. y-sell-capsule-business-for-up-to-1-billion.html
  Published in Business and Finance on Wednesday, January 28th 2026 at 7:04 GMT by reuters.com
      Locales: SWITZERLAND, UNITED STATES

ZURICH, January 28th, 2026 - Swiss contract drug manufacturer Lonza is reportedly on the verge of selling its capsule and health ingredients business for a potential price tag reaching up to $1 billion, according to sources familiar with the ongoing negotiations. The divestiture marks a significant step in Lonza's strategic pivot towards the high-growth, high-margin sectors of biopharmaceuticals and advanced therapies.

Lonza, a global leader in the pharmaceutical and biotech manufacturing space, initially signaled its intention to offload this segment of its operations several months ago. The company's decision reflects a broader industry trend - a refocusing of resources on more specialized and technologically advanced areas of drug development and production. While capsules and health ingredients represent a stable and consistent revenue stream, they offer comparatively lower growth potential than the increasingly complex world of biologics and cell/gene therapies.

Several potential buyers are still actively competing for the business, including a mix of private equity firms and established players within the pharmaceutical ingredient supply chain. Sources indicate that the competitive bidding process has kept valuation expectations high. The $1 billion figure represents a substantial return on investment for Lonza, providing capital that can be directly reinvested into expanding its biopharmaceutical capabilities.

This move isn't entirely surprising. Over the past few years, Lonza has been aggressively expanding its footprint in the biopharmaceutical sector, making substantial investments in new manufacturing facilities and technologies. They've partnered with numerous biotech companies, providing crucial contract development and manufacturing organization (CDMO) services - essentially acting as a manufacturing engine for innovative new drugs. The capsule and health ingredients business, while profitable, was becoming less strategically aligned with this overall direction.

However, the sale process hasn't been without its challenges. One source close to the deal confirmed that regulatory hurdles and standard due diligence procedures have caused some delays. The pharmaceutical industry is heavily regulated, and any change in ownership of a key ingredient supplier requires thorough scrutiny to ensure continued quality and supply chain integrity. Furthermore, the global landscape of pharmaceutical ingredient sourcing has become more complex in recent years, with increased emphasis on security of supply and geopolitical factors.

Experts suggest the acquisition would be attractive to both financial and strategic buyers. Private equity firms are always on the lookout for stable, cash-generating assets, and Lonza's capsule and health ingredients business certainly fits that profile. Strategic buyers, such as other pharmaceutical ingredient manufacturers or companies looking to vertically integrate their supply chain, could realize synergies and cost savings by adding Lonza's assets to their portfolio.

The health ingredients component of the business is particularly noteworthy. The market for nutritional supplements, vitamins, and other health-enhancing ingredients has seen significant growth in recent years, fueled by increasing consumer awareness of preventative healthcare and wellness trends. A new owner could potentially capitalize on this demand by expanding the product range and reaching new markets.

Lonza has maintained a strict policy of no comment throughout the sale process. Analysts anticipate that a formal announcement could be made within the next few weeks, assuming the final details are ironed out and regulatory approvals are secured. The company's next earnings call will likely provide further insights into the strategic rationale behind the divestiture and its plans for the future. Investors will be keenly watching how Lonza deploys the proceeds from the sale and whether it can successfully accelerate its growth in the competitive biopharmaceutical arena.

The implications of this deal extend beyond Lonza itself. It underscores the ongoing consolidation within the pharmaceutical supply chain and the increasing specialization of CDMOs. As drug development becomes more complex and expensive, companies are increasingly outsourcing manufacturing to specialized providers like Lonza, allowing them to focus on their core competencies of research and innovation.